DURHAM, N.C., Oct. 16 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) will make available a live webcast of its general shareholder meeting at 1:30 p.m. eastern time on Oct. 19, 2009.
The webcast will include the formal business meeting and the management presentation which will follow. During that presentation, management will provide an update on the company’s product development plans.
The webcast can be accessed via a link on the “Investors” page of the company website at www.oxybiomed.com. It can also be accessed directly via the following link: http://www.videonewswire.com/event.asp?id=61792.
A replay of the webcast will be archived on the company website for 90 days.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine™. The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte™) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.
SOURCE Oxygen Biotherapeutics, Inc.
Advertisement
The webcast will include the formal business meeting and the management presentation which will follow. During that presentation, management will provide an update on the company’s product development plans.
Advertisement
The webcast can be accessed via a link on the “Investors” page of the company website at www.oxybiomed.com. It can also be accessed directly via the following link: http://www.videonewswire.com/event.asp?id=61792.
A replay of the webcast will be archived on the company website for 90 days.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine™. The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte™) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.
SOURCE Oxygen Biotherapeutics, Inc.
